JP7478133B2 - 腎障害の処置で使用するための化合物 - Google Patents

腎障害の処置で使用するための化合物 Download PDF

Info

Publication number
JP7478133B2
JP7478133B2 JP2021504186A JP2021504186A JP7478133B2 JP 7478133 B2 JP7478133 B2 JP 7478133B2 JP 2021504186 A JP2021504186 A JP 2021504186A JP 2021504186 A JP2021504186 A JP 2021504186A JP 7478133 B2 JP7478133 B2 JP 7478133B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cpd
compound
once
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531308A (ja
JPWO2020021097A5 (enExample
Inventor
フォルノニ，アレッシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2021531308A publication Critical patent/JP2021531308A/ja
Publication of JPWO2020021097A5 publication Critical patent/JPWO2020021097A5/ja
Priority to JP2024068208A priority Critical patent/JP2024096989A/ja
Application granted granted Critical
Publication of JP7478133B2 publication Critical patent/JP7478133B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021504186A 2018-07-26 2019-07-26 腎障害の処置で使用するための化合物 Active JP7478133B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024068208A JP2024096989A (ja) 2018-07-26 2024-04-19 腎障害の処置で使用するための化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18185871.3 2018-07-26
EP18185871 2018-07-26
PCT/EP2019/070251 WO2020021097A1 (en) 2018-07-26 2019-07-26 Compounds for use in treating kidney disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024068208A Division JP2024096989A (ja) 2018-07-26 2024-04-19 腎障害の処置で使用するための化合物

Publications (3)

Publication Number Publication Date
JP2021531308A JP2021531308A (ja) 2021-11-18
JPWO2020021097A5 JPWO2020021097A5 (enExample) 2022-08-01
JP7478133B2 true JP7478133B2 (ja) 2024-05-02

Family

ID=63077813

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504186A Active JP7478133B2 (ja) 2018-07-26 2019-07-26 腎障害の処置で使用するための化合物
JP2024068208A Pending JP2024096989A (ja) 2018-07-26 2024-04-19 腎障害の処置で使用するための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024068208A Pending JP2024096989A (ja) 2018-07-26 2024-04-19 腎障害の処置で使用するための化合物

Country Status (13)

Country Link
US (3) US20200085810A1 (enExample)
EP (2) EP4537901A3 (enExample)
JP (2) JP7478133B2 (enExample)
KR (1) KR102860768B1 (enExample)
CN (2) CN112469442B (enExample)
AU (1) AU2019310919B2 (enExample)
CA (1) CA3104793A1 (enExample)
ES (1) ES3005632T3 (enExample)
IL (1) IL280368B2 (enExample)
MX (1) MX2021000976A (enExample)
PL (1) PL3826679T3 (enExample)
TW (1) TWI891608B (enExample)
WO (1) WO2020021097A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024096989A (ja) * 2018-07-26 2024-07-17 エフ． ホフマン－ラ ロシュ アーゲー 腎障害の処置で使用するための化合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022006277A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Methods for treatment of fibrotic kidney diseases
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504534A (ja) 2009-09-11 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩
JP2013509446A (ja) 2009-11-02 2013-03-14 サノフイ アシルアミノ置換された環式カルボン酸誘導体及び医薬としてのその使用
JP2014505063A (ja) 2011-01-26 2014-02-27 サノフイ 置換３−ヘテロアロイルアミノ−プロピオン酸誘導体及び医薬としてのその使用
JP2014516071A (ja) 2011-06-10 2014-07-07 エフ．ホフマン−ラ ロシュ アーゲー Ｃｂ２アゴニストとして有用なピリジン−２−アミド
WO2014180741A1 (en) 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
JP2016523943A (ja) 2013-07-10 2016-08-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 糸球体疾患の治療に使用するためのロスマピモド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270846B (it) 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
MXPA06010815A (es) 2004-03-26 2006-12-15 Hoffmann La Roche Tetrahidrocarbazoles y derivados de los mismos.
EP1756096B1 (en) 2004-05-03 2009-08-12 F.Hoffmann-La Roche Ag Indolyl derivatives as liver-x-receptor modulators
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
BR112014005634A2 (pt) 2011-09-12 2017-03-28 Hoffmann La Roche hidrazidas de 3-piridina ácido carboxílico como agentes de aumento de colesterol hdl
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504534A (ja) 2009-09-11 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩
JP2013509446A (ja) 2009-11-02 2013-03-14 サノフイ アシルアミノ置換された環式カルボン酸誘導体及び医薬としてのその使用
JP2014505063A (ja) 2011-01-26 2014-02-27 サノフイ 置換３−ヘテロアロイルアミノ−プロピオン酸誘導体及び医薬としてのその使用
JP2014516071A (ja) 2011-06-10 2014-07-07 エフ．ホフマン−ラ ロシュ アーゲー Ｃｂ２アゴニストとして有用なピリジン−２−アミド
WO2014180741A1 (en) 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
JP2016523943A (ja) 2013-07-10 2016-08-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 糸球体疾患の治療に使用するためのロスマピモド

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024096989A (ja) * 2018-07-26 2024-07-17 エフ． ホフマン－ラ ロシュ アーゲー 腎障害の処置で使用するための化合物

Also Published As

Publication number Publication date
PL3826679T3 (pl) 2025-03-10
KR20210038884A (ko) 2021-04-08
AU2019310919B2 (en) 2025-04-03
IL280368B1 (en) 2023-10-01
CA3104793A1 (en) 2020-01-30
JP2024096989A (ja) 2024-07-17
EP3826679B1 (en) 2024-11-27
EP4537901A2 (en) 2025-04-16
US20240325372A1 (en) 2024-10-03
TW202019486A (zh) 2020-06-01
JP2021531308A (ja) 2021-11-18
KR102860768B1 (ko) 2025-09-17
EP4537901A3 (en) 2025-05-21
AU2019310919A1 (en) 2021-01-07
US20200085810A1 (en) 2020-03-19
TWI891608B (zh) 2025-08-01
WO2020021097A1 (en) 2020-01-30
IL280368A (en) 2021-03-25
ES3005632T3 (en) 2025-03-14
US20210275514A1 (en) 2021-09-09
IL280368B2 (en) 2024-02-01
EP3826679C0 (en) 2024-11-27
EP3826679A1 (en) 2021-06-02
CN112469442A (zh) 2021-03-09
CN117736141A (zh) 2024-03-22
CN112469442B (zh) 2024-04-09
MX2021000976A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
JP2024096989A (ja) 腎障害の処置で使用するための化合物
JP2022500396A (ja) 疾患の処置用のファルネソイドｘ受容体アゴニスト
EP2200613B1 (en) Phenazine derivatives and uses thereof
JP7098214B2 (ja) 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用
EP2651403B1 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
RS54492B1 (sr) Kinazni inhibitor koji reguliše signalni put apoptoze
JP2019526582A (ja) 縮合二環式ｓｇｃ刺激剤
KR20170055531A (ko) 에스지씨 자극제
CN113924295A (zh) 激酶抑制剂
JP2023526055A (ja) 前立腺癌を治療する方法
KR101452518B1 (ko) Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
EP4346811A1 (en) Dual wnt signaling pathway inhibitors and ampk activators for treatments of disease
JP2016506918A (ja) イソメテプテン異性体
KR20220093330A (ko) Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
HK40102350A (zh) 用於治疗肾脏疾患的化合物
HK40040900B (zh) 用於治疗肾脏疾患的化合物
HK40040900A (en) Compounds for use in treating kidney disorders
AU2018223976A1 (en) Pharmaceutical compositions for combination therapy
TW201311249A (zh) Ｋｍｕｐ複合銨鹽類及高分子聚合物之改善高脂血及體重失衡療效
JP2025537202A (ja) Ｇｌｐ－１受容体作動薬とａｃａｔ阻害剤とを含む組成物（関連出願との相互参照） 本出願は、２０２２年１１月３日に出願され、参照により本明細書に組み込まれる、米国仮出願第６３／３８２，２８７号の優先権を主張するものである。
JP6352411B2 (ja) Ｄｐｐ−ｉｖ阻害剤を含有する腎疾患予防または治療用組成物
Radiosensitizer Azelnidipine Antihypertensive
HK1136563A (en) Indole compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240419

R150 Certificate of patent or registration of utility model

Ref document number: 7478133

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150